Trans-Tasman collaboration leads to new rotavirus vaccine
Thursday 4 September 2014
A new rotavirus vaccine that has the potential to save over half a million lives worldwide each year has reached a
pivotal milestone after clinical trials results found the vaccine provided a strong immune response in over 90 per cent
of babies that received a course of the vaccine.
Rotavirus is the most common cause of severe diarrhoea among infants and young children and results in the death of over
half a million children under five years of age worldwide each year, mainly in developing countries.
The clinical trial, which was done in collaboration between the University of Otago and the Murdoch Childrens Research
Institute at the University of Melbourne, involved 95 babies at Dunedin Hospital receiving a course of three doses of
the vaccine, with the first dose given within the first days of birth.
The breakthrough results will be presented at the 11th International Rotavirus Symposium currently underway in New
Delhi, India.
Lead researcher, Professor Julie Bines of Murdoch Childrens, the University of Melbourne and The Royal Children’s
Hospital said the results provide confidence that this vaccine will be very effective in preventing severe rotavirus
gastroenteritis in very young babies.
“These results are a major step forward for the development of the vaccine as it is the first time a rotavirus vaccine
has been given to newborns. Not only have we shown that this novel vaccine is well tolerated in newborns but it produces
a strong immune response in a newborn, suggestive of promoting early protection from severe gastroenteritis,” she says.
“The advantage of this vaccine over the currently available vaccines is the birth dose which is the earliest opportunity
to provide protection to babies from severe rotavirus gastroenteritis. This world-first approach has enormous potential
to reduce disease and dying in the most vulnerable children around the world.”
The ‘RV3’ Rotavirus Vaccine candidate has been developed from a unique strain of rotavirus that was found naturally in
healthy asymptomatic newborn babies, who were then protected from severe rotavirus diarrhea in the first two years of
life.
University of Otago Senior Clinical Lecturer in Women and Children’s Health Dr Pam Jackson says the clinical trial in
Dunedin went very well, and she thanks families for their participation, and also the Health Research Council (HRC) of
New Zealand, which funded the study.
“Without their willingness to help this would have been difficult to assess, and we are delighted that this vaccine has
been shown to be an effective way to prevent this disease.”
Newborn babies and infants in Dunedin were given three doses of the oral vaccine, called RV3-BB, or a placebo to
ascertain the level of immunity to rotavirus generated by the vaccine. The vaccine is derived from a harmless strain of
rotavirus found in newborn babies. In New Zealand, rotavirus is responsible for 1500 hospital admissions of children
under five years of age each year.
Although babies in Australia have had the benefit of rotavirus vaccines the new vaccine has a number of advantages, such
as the ability to administer earlier and prevent disease in very young babies that are currently not protected.
The research and development of the ‘RV3’ vaccine is being led and conducted by academic institutions rather than the
pharmaceutical industry with the intention to partner with developing country manufacturers so that the vaccine will
ultimately be affordable for developing countries, where they are needed most.
The vaccine is the culmination of over four decades of research in Australia by the Murdoch Childrens Research
Institute, The Royal Children's Hospital Melbourne and the University of Melbourne, following the discovery of rotavirus
by a team of staff led by Professor Ruth Bishop in 1973.
Clinical trials are also underway in Indonesia. It is hoped the vaccine will be available for widespread use in 2016.
ends